No Data
No Data
xiamen kingdomway group (002626.SZ): Currently, the main revenue-generating products include finished nutritional health food, coenzyme Q10 series raw materials, and vitamin A series raw materials
Grain Information on October 15: Xiamen Kingdomway Group (002626.SZ) stated on the investor interaction platform that the company's main revenue-generating products currently include finished nutritional health food, coenzyme Q10 series raw materials, and vitamin A series raw materials. According to the semi-annual report for 2024, their respective proportions of revenue are 63.41%, 24.92%, 4.14%.
Xiamen Kingdomway Group (002626.SZ): The company and its wholly-owned subsidiary have obtained a US invention patent certificate.
On October 14, Xiamen Kingdomway Group (002626.SZ) announced that the company and its wholly-owned subsidiary Xiamen Kingdomway Bio-Tech Co., Ltd. recently received an invention patent certificate issued by the United States Patent and Trademark Office. The invention is titled 'Method for preparing modified starch, liposome, and method for preparing liposome'. This invention belongs to the food or medical field, involving a method for preparing modified starch, liposome, and method for preparing liposome. The liposome prepared by the modified starch of this invention has good stability, encapsulation efficiency, and bioavailability.
xiamen kingdomway group (002626.SZ): Vitamin D3 accounts for a small proportion of the company's business.
Gelonghui October 11th | Xiamen Kingdomway Group (002626.SZ) stated on the investor interaction platform that the proportion of vitamins D3 in the company's business is relatively small and does not meet disclosure standards. Due to business reasons, the company has not authorized the disclosure of related costs. The recent fluctuation in the market price of vitamins D3 is not directly related to cost changes.
Xiamen Kingdomway Group (SZSE:002626) Has A Rock Solid Balance Sheet
Xiamen Kingdomway's Unit Receives Production License to Produce Inositol
Xiamen Kingdomway Group (002626.SZ): Inner Mongolia Xiamen Kingdomway Pharmaceutical Co., Ltd. has obtained the fodder additive production license.
Gelonghui on September 23rd | Xiamen Kingdomway Group (002626.SZ) announced that its wholly-owned subsidiary, Inner Mongolia Xiamen Kingdomway Pharmaceutical Co., Ltd., recently received the "Fodder Additive Production License" issued by the Inner Mongolia Autonomous Region Department of Agriculture and Animal Husbandry, adding a production license for "inositol". Inositol is a B-vitamins widely present in animals and plants, essential for the growth of microorganisms and animals.
No Data
No Data